COMP <GO>
MANE vs JNJ // FORWARD P/E MULTIPLE
Veradermics Incorporated (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MANE 2
— JNJ 9
▲ FORWARD P/E MULTIPLE LEADER: JNJ
LAST: $143.85 (+0.01%) • MKT CAP: $6.01B
forward-pe
24.0x
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MANE VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MANE | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.90% | 25.50% | -37.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.19% | 2.97% | -4.16 | JNJ | /fcf-yield <GO> |
| Operating Margin | -4.30% | 34.70% | -39.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -4.20% | 28.50% | -32.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 4.40% | 6.00% | -1.60 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | MANE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.6 | 62.1 | +3.50 | MANE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.08 | -0.01 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 24.0x | 23.0x | +1.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.01B | $662.49B | -$656.48B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MANE REV | JNJ REV | MANE GROSS % | JNJ GROSS % | MANE FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$71.6M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$23.7M | $19.84B |
| FY 2023 | — | $85.16B | — | — | — | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MANE // BETA 1.07
JNJ // BETA 1.08